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 Nobody ever figures out what life is all about, and it doesn't matter. Explore the world. 
Nearly everything is really interesting if you go into it deeply enough. 
Richard P. Feynman  
 
  
  
  
ABSTRACT 
 
Background Critically ill patients suffer from protein catabolism with losses of skeletal 
muscle and whole-body proteins associated with morbidity and mortality. Catabolism is 
difficult to overcome, but nutritional supplementation with enteral protein or parenteral 
amino acids may limit protein losses. It is unknown which dose, mode, and timing of feeding 
is optimal for critically ill patients. 
Aim The aim of this project was to evaluate a technique of quantifying the response of 
protein turnover to feeding, then apply it to study effects of protein or amino acid 
supplementation in critical illness. A main question was whether exogenous protein/amino 
acid is utilized for improved protein balance, or else consumed in catabolic pathways. 
Methods In study 1, a previously characterized cohort of viscerally obese, insulin-resistant 
women was studied. Postprandial muscle and whole-body protein turnover were quantified 
by stable-isotope labeled phenylalanine tracers. In study 2, the whole-body technique was 
adapted to investigate the effects of early enteral feeding in critically ill patients. In study 3, 
the response of critically ill patients to a three-hour course of intravenous supplemental amino 
acids was studied. In study 4, the time course of uptake of stable-isotope-labeled 
phenylalanine from the intestine into arterial blood was studied in healthy subjects and 
critically ill patients during continuous enteral feeding. 
Results In study 1, the technique was found workable to quantify postprandial protein 
metabolism, and it was found that viscerally obese women are resistant to postprandial 
stimulation of anabolism. In study 2, it was found in critically ill patients that enteral feeding 
of a small amount of protein yields a detectable gain in protein balance and no increase in 
amino acid oxidation. In study 3, an improvement in whole-body protein balance after three 
hours of intravenous amino acid supplementation was found in critically ill patients. In 
study 4, the uptake of dietary phenylalanine from continuous enteral feeding was found to 
reach a tentative steady state, but with high intra- and interindividual variability. 
Conclusion Exogenous amino acids from enteral or intravenous nutrition improve protein 
balance in healthy subjects and critically ill patients, and are not predominantly consumed in 
catabolic pathways. 
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1 INTRODUCTION 
 
Critically ill patients universally suffer from protein catabolism and associated morbidity and 
mortality. Protein catabolism is difficult to overcome, but nutritional supplementation has 
shown beneficial effects in observational studies. Nutritional strategies make use of enteral or 
parenteral supply of amino acids, though it is not well understood how the metabolism of 
critically ill patients reacts to such supply. 
In the work here presented, the response to feeding in adult human subjects was investigated, 
with a focus on patients in the intensive care unit (ICU). Protein metabolism was assessed by 
quantifying whole-body and skeletal-muscle protein turnover, using intravenous and 
intragastric/enteral infusions of stable-isotope labeled phenylalanine and tyrosine tracers.  
1.1 CRITICAL ILLNESS AND PROTEIN CATABOLISM 
1.1.1 Critical illness 
Critical illness emerged in the 20th century with technological advances such as mechanical 
ventilation, renal support, and advanced hemodynamic monitoring and pharmacotherapy. It is 
in some measure an artificial disease, as it occurs in conditions that are hardly survivable in 
their natural course. Challenges in critical care medicine arise from the necessity to handle 
physiological processes far outside their normal equilibria, where adaptive - or maladaptive - 
responses may react to intervention in unpredictable ways. For the same reason, extrapolation 
from the physiology of less severe disease or health may be inappropriate when studying the 
physiology of critical illness. 
Although the causes of critical illness are diverse, many patients exhibit a 
phenomenologically rather uniform, multiphasic course of illness, characterized by 
multiorgan dysfunction and secondary morbidity. It is increasingly recognized that the 
pathophysiology and the spectrum of morbidities differ significantly between the early acute 
phase in the first few days of critical illness, the ensuing late acute phase, and a prolonged 
post-acute phase thereafter1-4, and that ICU survivors may suffer chronic infirmity and late 
mortality5,6. 
1.1.2 Body composition 
Changes in body composition are common in critical illness7. Along with changes of energy 
expenditure and body water content, loss of lean body mass is typical of critical illness8, with 
excessive loss of skeletal muscle9 and whole-body protein10. Skeletal muscle is quantitatively 
the dominant component of lean body mass. In the ICU, quantifying body composition, and 
especially skeletal muscle mass11, may be difficult. Physical anthropometric measurements 
are unreliable due to varying degrees of edema. Techniques such as dual X-ray 
absorptiometry, neutron activation analysis, and magnetic resonance imaging offer theoretical 
advantages, but are problematic in practice because of logistic challenges and lack of 
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validation in relevant populations12. Computed tomography and ultrasound imaging are 
clinically applicable techniques13 and have been used in observational studies to quantify the 
loss of muscle mass14 and muscle quality15. By these techniques it was also demonstrated that 
macroscopic loss of muscle mass correlates with higher morbidity and poor outcome in 
critical illness9,16. Bioimpedance analysis is increasingly used to quantify lean body mass in 
ICU patients17. 
1.1.3 ICU acquired weakness 
Critically ill patients typically lose both mass and function of skeletal muscle, but muscle 
wasting is not synonymous with ICU acquired weakness (ICUAW)18,19, and the causal 
relationship between the two phenomena is not completely understood20. The etiology of 
ICUAW is multifactorial, and factors such as inflammation, sepsis, multiorgan failure, 
immobilization, age, medications, and hyperglycemia may all be involved21. Both critical 
illness polyneuropathy (CIP) and critical illness myopathy (CIM) may contribute to the 
development of ICUAW19,22, and the precise etiology in individual cases may be difficult to 
determine. Because a stringent evaluation of ICUAW requires the patient’s cooperation, 
diagnosis is in practice based on clinical tests that carry inherent limitations21. ICUAW may 
affect the respiratory muscles, and the subsequent need for prolonged ventilatory support 
poses a major clinical problem23. ICUAW contributes to both in-hospital and long-term 
mortality24 and to long-term loss of function21,25. Although a majority of ICU survivors 
recover from the sequelae of ICUAW, others suffer from persistent infirmity up to several 
years after ICU admission25. 
1.1.4 Mechanisms of muscle wasting 
Skeletal muscle undergoes a constant turnover of its protein components by catabolism, i.e. 
proteolysis and AA release, and anabolism, i.e. AA uptake and protein synthesis. To some 
degree, this turnover occurs within muscle tissue itself, constituting a local recycling of AA. 
However, muscle protein metabolism is also integrated into the organism’s overall AA 
exchange. In that respect, skeletal muscle serves as a reservoir of AA, as mammalian 
physiology otherwise lacks organs or tissues for long-term protein storage. 
Phenomenologically, muscle wasting in critical illness is characterized by fiber atrophy or 
necrosis9,26,27. The loss of lean body mass is driven by an increase of protein breakdown in 
skeletal muscle9,28 that occurs largely in the early phases of illness and is mediated by both 
the proteasome and the lysosomal proteolytic enzyme systems29. Accelerated muscle protein 
breakdown coincides with an increased global protein turnover and a net flow of AA from 
skeletal muscle to the liver, lymphatic organs, and site of injury28,30,31. It is speculated that 
this mechanism serves to maintain protein synthesis in these sites, as well as hepatic 
gluconeogenesis32. 
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1.1.5 Anabolic stimuli and anabolic resistance 
Anabolic resistance is a term used to describe a reduced sensitivity of skeletal muscle to 
protein anabolic stimuli. It is seen in a variety of circumstances such as aging, inactivity, 
obesity, chronic kidney disease, chronic lung disease, and cancer. Mechanisms of anabolic 
resistance have been studied in various physiological and pathological conditions. 
Immobilization impairs the ability of skeletal muscle to react to AA provision33. In higher 
age34, the response of skeletal muscle to the major anabolic stimuli - exercise, AA 
availability, and insulin - is altered through various mechanisms such as splanchnic 
sequestration of dietary AA35, impaired insulin-mediated capillary recruitment36, and altered 
AA transporter and signaling activity37. On the cellular level, the response to anabolic stimuli, 
specifically by the mammalian target of rapamycin (mTOR) pathways38, is attenuated in 
aging subjects, but also in sepsis39.  
1.1.6 Anabolic resistance in critical illness 
Several causes of anabolic resistance converge in critical illness, but their respective roles in 
the pathophysiology of muscle wasting are far from clear32,38,40. Immobilization removes a 
major stimulus of skeletal muscle anabolism. Non-pediatric ICUs typically have a large 
proportion of older patients who may be anabolically resistant by virtue of age. Although 
insulin promotes protein anabolism by several pathways, including recruitment of 
microvascular nutritive flow, the role of insulin resistance in muscle wasting of critical illness 
is not clear32. Availability of AA for muscle protein synthesis may be abnormal in septic 
patients, in that AA efflux from muscle cell to interstitium and venous blood is increased, 
while AA from arterial blood are shunted past the interstitium and muscle cell41. Glucagon 
acts as a catabolic signal regulating hepatic AA breakdown, and plasma AA stimulate islet α-
cell growth in a feedback cycle independent of the glucose-insulin axis42. This mechanism is 
active in critically ill patients and in an experimental model of critical illness, where it 
interferes with feeding in the early phase of critical illness, in that exogenous AA 
supplementation accelerate AA breakdown, though apparently without effect on muscle 
wasting43. A derangement of the hypothalamic-pituitary-adrenocortical axis is seen in critical 
illness, characterized by elevated total and free plasma cortisol concentrations and low 
adrenocorticotropic hormone plasma concentrations44. Muscle wasting is characteristic of 
hypercortisolism and is partly mediated by direct and indirect inhibition of insulin action on 
skeletal muscle protein turnover45. Finally, systemic inflammation32, hypoxia46, and uremia47 
may further impair stimulation of anabolism. Thus, a variety of epidemiological, biophysical, 
hormonal and biochemical factors contribute to a milieu in the ICU that is hostile to gain or 
maintenance of body protein. 
1.2 INTERVENTIONS TARGETING PROTEIN CATABOLISM IN CRITICAL 
ILLNESS 
Pharmacological, physical, physiotherapeutic and nutritional strategies against protein 
catabolism and muscle wasting have been investigated.  
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1.2.1 Non-nutritional 
Various pharmacological interventions have been investigated or are theoretically viable48-50. 
Human growth hormone is theoretically attractive as an anabolic agent and may be safe in 
specific patient groups48,51, but was found to increase mortality of critically ill patients in 
large randomized trials52. The β-adrenergic receptor blocker propranolol48,53 and the 
testosterone analog oxandrolone54 have beneficial effects on lean body mass in children with 
severe burns, but have not gained ground in other ICU populations. Insulin, as a major 
physiological anticatabolic signal, is a plausible candidate drug. In a small trial in surgical 
patients, intensive insulin treatment during parenteral nutrition was associated with greater 
muscle protein synthesis and less negative nitrogen balance55. However, an independent role 
of exogenous insulin may be difficult to define because of the highly regulated homeostatic 
function of endogenous insulin secretion, as well as varying nutrient supply, varying degree 
of insulin resistance, and heterogeneity of ICU populations in general. 
The biguanide metformin inhibits hepatic glucagon signaling56,57 and appears to have an 
anticatabolic effect in severe burn injury58,59. Metformin improves insulin sensitivity when 
used for glycemic control in patients with severe burn injury60. Its use in general ICU 
populations remains to be explored. The leucine metabolite β-hydroxy β-methylbutyrate 
(HMB) acts as an anabolic signal on muscle protein metabolism61, improves muscle mass in 
sarcopenia62, and in conjunction with protein supplementation improves mortality in 
malnourished hospitalized patients63. In one RCT, hydroxymethylbutyrate had no effect on 
femoral muscle volume of critically ill patients64.  
Neuromuscular electrical stimulation was investigated in several studies and found in 
some65,66, but not others67, to improve muscle strength. Methodological questions remain68, 
and the strength of currently available evidence is limited by the heterogeneity of methods 
and outcomes studied65,66. Functional challenge is an important stimulus of protein anabolism 
in skeletal muscle, and its absence in the immobilized ICU patient appears to play a major 
role in muscle wasting28,69. Interventions such as physiotherapy, reduced sedation, and early 
mobilization were found to improve muscle function70-72 and ICU outcomes53,71-74, but may 
be difficult to implement in practice21,75. Thus, increased physical activity is likely to improve 
ICU outcomes, but the heterogeneity of protocols and outcome measures limit the 
generalizability of such findings11. 
1.2.2 Nutritional support 
Nutritional support is an essential therapeutic modality in critical care and has a role in 
modulating protein catabolism. Effects of nutritional support have been studied on all scales 
from physiological investigations in a few subjects to multicenter RCTs with several 
thousand patients. The following sections mostly focus on recent research, the rationale being 
that ICU treatment protocols in general - and feeding strategies specifically - are undergoing 
such a rapid change that older findings might not be applicable to patient populations 
currently treated at ICUs. 
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1.2.3 Protein/amino acid dose 
It is well established that appropriate protein/AA provision is required to minimize 
catabolism, but there is much uncertainty over protein requirements in critical illness76,77, and 
timing78, route, and dose of protein/AA supplementation79,80. The existing uncertainty is 
partly due to methodological obstacles that affect ICU nutrition studies in general81, such as: 
- observational and/or retrospective study designs 
- heterogeneity of ICU populations 
- heterogeneity of study protocols 
- heterogeneity of endpoints 
- multiple confounding factors, due to the complexity of medical protocols and the 
physiology of critical illness itself. 
One other problem more specific to studies of protein/AA dose is the fact that many studies 
do not consider protein/AA supplementation separately from total nutrient content. Taken 
together, these factors complicate any generalization of findings or generation of clinical 
recommendations2,82. Current recommendations stipulate a protein dose that is far lower than 
what is considered the highest safe intake in health83. On the whole, high level evidence 
supporting specific protein targets is scarce76,79,84-86 and more research in this topic is 
considered a high priority77. 
1.2.4 Protein/amino acid dose and ICU outcomes – observational and 
retrospective studies 
A relationship between protein/AA dose and ICU morbidity and mortality is reported in 
observational studies2. Weijs et al.87 investigated 886 ICU patients in a prospective 
observational study design and found that patients where both energy and protein targets were 
reached had a lower mortality than those where only energy targets were reached. In a 
reanalysis of 843 patients from that cohort88 it was found that energy overfeeding and sepsis 
were independent risk factors for mortality; in non-septic, non-overfed patients, a high 
protein intake was associated with better survival. Allingstrup et al.89 found in 113 ICU 
patients that higher protein supply correlated with better survival, while measured resting 
energy expenditure, energy supply, or nitrogen balance had no effect. Nicolo et al.90 
retrospectively analysed 2828 patients and found higher survival when > 80 % of protein 
targets was reached, while higher energy intake did not affect survival. Elke et al.91 analyzed 
2270 patients with sepsis or pneumonia and found higher protein and caloric intake 
associated with higher survival. Compher et al.92 found an association between protein intake 
and survival in several subgroups of a 2853 patient sample. Investigations by Song et al.93 
and Zusman et al.94 came to similar conclusions. In a post hoc subgroup analysis of 729 
patients in the PermiT RCT95, patients were stratified into lower or higher enteral protein 
dose (with corresponding differences in caloric intake), and no difference in mortality was 
found,  but higher protein intake was associated with higher urinary urea excretion. Finally, 
Koekkoek et al.96 retrospectively analysed 445 patients and found that both overall low 
protein intake and early high protein intake was associated with higher mortality.  
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To summarize, evidence from observational studies generally supports an association 
between higher protein/AA intake and better outcomes. However, given the difficulties of 
feeding ICU patients, one reasonable interpretation might be that patients with a more stable 
physiology and better prognosis are more easily fed. Thus, these findings support, but do not 
prove, a causal role of higher dose protein supplementation for better ICU outcomes. 
1.2.5 Protein/amino acid dose and ICU outcomes – interventional studies 
Several interventional studies have targeted supplemental parenteral nutrition resulting in 
both higher caloric and higher AA supply97-100, or different doses of enteral nutrition at 
identical daily protein/AA dose101-103. However, there are few published results from newer 
RCTs where the relationship of protein/AA dose and ICU outcomes was studied independent 
of total nutrition dose, although more RCTs are under way104,105.  
In the study by Ferrie et al.106, 120 patients were randomized to receive either 1.2 or 
0.8 g AA/kg BW per day, with doses actually delivered of 0.9 and 1.1 g/kg BW per day. 
Better handgrip strength and better nitrogen balance were seen in the higher-AA group at 
various timepoints. However, early energy intake was lower in the higher-AA group, and 
selection bias due to differences in mortality risk cannot be excluded107. 
In one RCT by Rugeles et al.101, 115 patients were randomized to either high-protein or 
standard-protein hypocaloric enteral nutrition, with doses actually delivered of 12 kcal/kg 
BW and 1.4 g protein/kg BW per day vs. 14 kcal/kg BW and 0.76 g protein/kg BW per day. 
Patients in the high-protein group had slightly better Sequential Organ Failure Assessment 
(SOFA) scores. However, there was substantial risk of selection bias due to patients leaving 
the ICU early, and mortality was not reported in the per-protocol analysis.  
In the Nephro-Protective Trial, a multicenter RCT designed to study acute kidney failure as 
the primary outcome108, 474 patients were randomized to receive either standard nutrition or 
an additional supplement of intravenous AA, with doses delivered being 0.75 vs. 
1.75 g AA/kg BW per day. There were between-group imbalances in baseline renal morbidity 
and severity of illness. Patients in the high-AA group had slightly shorter duration of 
respiratory failure and somewhat higher urine output and estimated glomerular filtration 
rates, but also higher fluid intake, higher serum urea concentration, and possibly greater use 
of renal replacement therapy. These findings show that AA dose had little effect on ICU 
morbidity, but the difference in serum urea values suggest that exogenous AA at the higher 
dose may not have been utilized for protein anabolism. A post hoc subgroup analysis109 
revealed that patients with kidney dysfunction or risk of progression of acute kidney failure at 
baseline did not benefit from the AA supplement, while patients without these risk factors 
who received the supplement had a lower mortality compared with those who did not. 
In conclusion, evidence from prospective interventional trials where different AA doses were 
compared in isolation shows that higher-dose AA supplementation may confer some benefit 
in biochemical, biomechanical, and severity-of illness parameters, and possibly in mortality. 
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1.2.6 Protein/amino acid dose – experimental studies 
Complementing ICU outcome studies, protein requirements in critical illness can be studied 
experimentally. This can be done by calculating nitrogen balance, i.e. measuring total intake 
of protein/AA and output of AA metabolic products over a period of time, or by measuring 
protein turnover using AA tracers. These techniques are discussed in more detail below in the 
context of the quantification of protein turnover.  
In a prospective randomized experimental study in trauma and burn patients110, a less 
negative cumulative 7-days nitrogen balance was seen with AA supply of up to 0.7 g/kg BW 
per day, but not above that level; an extrapolation beyond that specific patient cohort may not 
be warranted. In a nonrandomized study in trauma and sepsis patients111, a protein dose of 
1.2 g/kg preadmission BW was found to optimally support body protein mass. In an 
extensive review of the literature on protein requirements in the ICU80, it was found that all 
available experimental studies showed methodological weaknesses, such as measurement 
during energy overfeeding, and inappropriate or unclear calculation of AA doses. Most 
available studies used nitrogen balance as outcome measure. Protein/AA doses varied from 0 
to 2.8 g/kg BW per day. Due to the great heterogeneity of patient populations and study 
protocols, it is impossible to reconcile their results and define a single protein/AA dose that 
optimally maintains body protein76. However, it can be concluded that higher protein/AA 
supply generally appear to increase short-term nitrogen balance, that maintenance of whole-
body protein may require a protein/AA dose in the region of 1.2 – 1.5 g/kg BW per day76, and 
that an upper limit may be difficult to define80.  
1.2.7 Amino acid composition 
Nutritional supplementation with individual AA - e.g. glutamine, leucine, arginine, or 
citrulline - can experimentally be shown to increase protein anabolism, but it remains 
controversial whether any such intervention improves ICU outcomes61,107,112. In the most 
recent European guidelines2, AA composition in nutritional support is not specifically 
addressed, apart from recommendations to abstain from enteral glutamine supplementation 
except for burns or trauma, and to abstain from parenteral glutamine supplementation in 
complex cases and patients with unstable physiology.  
1.2.8 Current recommendations on protein dose 
Despite the limitations of available evidence, attempts have been made to synthesize current 
knowledge into clinical guidelines. This was most recently done in 2018 by the European 
Society for Clinical Nutrition and Metabolism after thorough review2, in a revision to 
previous guidelines113,114. Based on strong consensus among the guideline’s authors and 
reviewers, the current recommendation is that 1.3 g protein equivalent/kg BW per day can be 
delivered progressively to patients in the ICU2. In the corresponding American guidelines115, 
a very low quality of evidence is noted. It is suggested that “sufficient (high-dose) protein 
should be provided”, that “protein requirements are expected to be in the range of 1.2–
2.0 g/kg actual body weight per day and may likely be even higher in burn or multitrauma 
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patients”, and that “aggressive high-protein EN therapy” should be used in chronical critical 
illness. 
1.2.9 Monitoring protein nutrition 
It is recognized that risks, effects, and complications of nutrition in the ICU should be 
monitored, but the use of monitoring is not sufficiently studied116. For monitoring the effects 
of protein supply, few methods are practically available. Available measurements of body 
composition lack feasibility in the ICU setting and are therefore not widely used. Estimations 
of daily nitrogen balance can be made based on urinary urea losses, but are imprecise, and 
may not be useful in settings of rapid metabolic change. More exact measurements of 
nitrogen balance are usually not feasible in the ICU setting117. Measurements of blood urea 
and ammonia may detect overt protein overfeeding116, but their interpretation is complicated 
by effects of organ dysfunction and comorbidities. Plasma aminograms are a useful research 
tool. ICU patients with sepsis show a wide variation in plasma aminoacidemia and several 
parameters derived from the aminogram correlate with severity of illness and survival118-120. 
However, measurements of plasma AA require specialized equipment and are not clinical 
routine in the ICU. The usefulness of other routine laboratory analyses for monitoring of 
protein nutrition is not established.  
1.2.10 Negative effects of nutritional support in critical illness 
Possible risks of early nutritional support in critical illness are increasingly recognized. 
Subgroup analyses of large RCTs in adult121 and pediatric122 critically ill patients have shown 
that early full-dose nutritional support is associated with higher complication rates. From 
these data, it appears that specifically AA, but not other macronutrients, are implicated122. An 
antagonism of autophagy is discussed as a physiological mechanism123. Autophagy is a 
cellular mechanism that is activated by inflammation, hypoxia and various other stressors124 
and modulated by availability of nutrients, especially AA125. Previously thought of as a 
pathway to cell death, autophagy is nowadays rather considered an essential housekeeping 
mechanism. It may have an adaptive role in critical illness and its inhibition by early nutrition 
may be detrimental126, although inhibition of autophagy on a cellular level can be shown in 
only a fraction of critically ill patients127. Even if the pathophysiology remains unclear, 
current guidelines discourage early full-dose feeding, and note that intentional hypocaloric 
feeding may be safe in certain circumstances2,78. 
1.3 SUMMARY 
Protein catabolism in critical illness is common, difficult to ameliorate, and insufficiently 
understood. While nutritional strategies appear promising, the physiology of protein/AA 
feeding in critical illness is not sufficiently characterized, and it remains unclear how 
nutrition should be composed, dosed, delivered, timed, and monitored to give the greatest 
possible benefit to specific individuals or patient groups. 
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2 AIMS 
 
The overall aim of this project was to mechanistically study the effects of protein/AA 
supplementation on protein turnover in critical illness. We sought to establish a technique of 
measuring whole-body protein turnover by stable-isotope labeled phenylalanine/tyrosine 
tracers, then apply it to quantify the effects of parenteral and enteral protein/AA feeding on 
protein metabolism in critically ill patients. A central question was whether exogenous 
protein/AA is utilized for improved protein balance, or else consumed in catabolic pathways.  
2.1 RESEARCH QUESTIONS FOR STUDIES 
Study 1: Quantify the postprandial response of muscle and WB protein turnover by stable-
isotope labeled phenylalanine tracers in a previously characterized population of viscerally 
obese, insulin-resistant subjects. 
Study 2: Quantify the postprandial response of WB protein turnover to an initial dose of 
continuous enteral feeding by intravenous and enteral stable-isotope labeled 
phenylalanine/tyrosine tracers in healthy volunteers and patients in an early phase of critical 
illness.  
Study 3: Evaluate the usability of a free phenylalanine tracer to quantify the availability of 
dietary protein from continuous enteral feeding in critically ill patients; and quantify the 
response of WB protein turnover to a three-hour course of supplemental parenteral AA in 
patients at two time points during the postacute phase of critical illness. 
Study 4: Characterize the time course of uptake into arterial blood of dietary isotope labeled 
phenylalanine during continuous enteral feeding in healthy subjects and critically ill patients. 
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3 STUDIES OVERVIEW 
 
3.1 STUDY DESIGN AND EXPERIMENTAL PROTOCOLS 
An overview of study designs is shown in Table 1 and an overview of nutrition and tracers 
used in Table 2. The details can be found in the individual papers. 
3.2 LOGISTICS AND EXECUTION, RECRUITMENT, DATA ACQUISITION 
Study 1 is a retroactive analysis of data that had been obtained, but previously not analyzed or 
published, in conjunction with another set of experiments128 at Endocrine Research Unit, 
Mayo Clinic, Rochester, Minnesota, USA. Studies 2-4 were executed at the experimental 
facility and the ICU of the Department of Perioperative Medicine and Intensive Care 
(formerly Department of Anesthesia and Intensive Care), Karolinska University Hospital 
Huddinge in Stockholm, Sweden. 
For study 1, volunteers were recruited in accordance with the host institution’s regulations 
and as stipulated by the relevant Ethics Review Board (ERB) decisions. For studies 2 and 4, 
healthy subjects were recruited from the department’s volunteer database and informed 
consent was obtained in accordance with Swedish law and as stipulated in the ERB decisions. 
For studies 2-4, patients were recruited from the department’s ICU and informed consent was 
obtained from them or from their next of kin, in accordance with Swedish law and as 
stipulated in the ERB decisions.  
For study 1, anthropometric and clinical data were obtained in conjunction with the earlier 
investigation 128. For patients in studies 2-4, anthropometric and clinical data were obtained 
from hospital records and from the ICU’s patient data management system. For healthy 
subjects, relevant information was obtained by interview, and where appropriate from 
hospital records. For study 1, laboratory analyses were performed at the host institution. For 
studies 2-4, laboratory analyses were performed at the department’s research laboratory. 
3.3 ETHICAL CONSIDERATIONS 
Study 1 was approved by Mayo Institutional Review Board at Mayo Clinic, Rochester, 
Minnesota, USA. Studies 2-4 were approved by the regional ERB in Stockholm. Assessments 
of risk and benefit to individual study subjects included in the Stockholm ERB applications 
concluded that participation in the experiments carried minimal risks, insofar as: medical 
procedures followed established standards, were performed by qualified staff and in the 
setting of the department’s ICU and experimental facilities; additional procedures were 
limited to study nutrition, tracer infusion, and sampling and – for healthy subjects – 
placement of nasogastric feeding tubes, arterial, and venous catheters; risk associated with 
exposure to study nutrition and tracers was minimal; and blood loss by sampling was 
minimized to safe levels.  
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3.4 REGISTRATION 
Study 2 was registered at Australian New Zealand Clinical Trials Registry, with registration 
number ACTRN12614000333617, and study 4 with registration number 
ACTRN12616000593437. 
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4 METHODS 
 
4.1 PHYSIOLOGY AND IN VIVO QUANTIFICATION OF PROTEIN TURNOVER 
All models are wrong, but some are useful * 
4.1.1 Protein turnover 
Protein metabolism is unique in its functions and its regulation. AA serve a unique variety of 
physiological roles, from building block of protein to signaling molecule in metabolism, to 
reserve energy fuel, and to precursor for bioactive small molecules, such as hormones, 
transmitters and signaling molecules, with a vast number of biological functions129.  
The protein content in all tissues undergoes a constant turnover, i.e. cycling, of AA through 
protein synthesis and breakdown130,131. In the adult human, WB protein turnover is estimated 
to be 4 g/kg BW per day, i.e. three to four times the dietary intake132,133. Turnover varies 
widely between organs and tissues, with liver and intestine representing 50% of WB turnover 
at only 8% of lean body mass, while skeletal muscle accounts for 25% of WB turnover at 
55% of lean body mass130. Protein turnover is not energetically cheap and in a normal adult is 
estimated to account for 20% of the basal metabolic rate130. As the daily total amount of AA 
cycling substantially exceeds dietary protein intake, a fine-tuned regulation both in individual 
tissues and the organism as a whole is necessary to maintain both homeostasis and 
adaptability134.  
Sources of AA are dietary intake, proteolysis, and - for non-essential AA - endogenous 
synthesis. While there appears to be a buffer, or short-term storage, of mainly dietary AA in 
the intestine135, there is no long-term storage of AA outside functional tissues. Instead, 
skeletal muscle serves as the major reservoir of AA when dietary AA are not available. AA 
concentrations in individual cells, tissues, and the organism as a whole are homeostatically 
controlled to minimize loss through AA oxidation134. AA from protein breakdown are either 
recycled locally within organs or tissues, or released into the circulation as free AA. Free AA 
constitute only 2% of the body’s total AA content136 but serve as a vehicle for substrate traffic 
between organs and tissues. A constant exchange through the blood circulation distributes 
AA for interorgan traffic130. Interorgan traffic is an active and regulated process137 that 
involves transportation of free AA, peptides and proteins by blood and lymph circulation. 
Different organs and tissues have widely varying content of individual AA and distinct 
metabolic patterns129. For example, skeletal muscle serves as a site of synthesis for glutamine 
                                                 
* Alternatively, ‘Since all models are wrong the scientist cannot obtain a "correct" one by excessive elaboration. 
On the contrary following William of Occam he should seek an economical description of natural phenomena. 
Just as the ability to devise simple but evocative models is the signature of the great scientist so overelaboration 
and overparameterization is often the mark of mediocrity.’ George Box, Science and Statistics. Journal of the 
American Statistical Association, 1976, Vol. 71, pp. 791-799 
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and alanine which it exports to other organs where these AA are used for specific metabolic 
functions (Fig. 1)138. 
 
 
 
Figure 1 Inter-organ metabolism of branched-chain amino acids, glutamine and arginine, 
and their role in immune function. Skeletal muscle takes up BCAA from the arterial blood, 
synthesises both alanine and glutamine from BCAA and α-ketoglutarate, and releases these 
two amino acids into the circulation. The small intestine utilises glutamine to synthesise 
citrulline, which is converted into arginine in kidneys, cells of the immune system and other 
cell types. The liver is the primary organ for the synthesis of glutathione from glutamate, 
glycine and cysteine, and of glucose from alanine for use by extrahepatic cells (including 
leukocytes) and tissues. Abbreviations: Arg, arginine; Asp, aspartate; Cit, citrulline; BCAA, 
branched-chain amino acids; BCKA, branched-chain α-ketoacids; Gluc, glucose; GSH, 
glutathione. 
Image and caption source: 138. Reproduced by permission. 
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The splanchnic organs have a highly active AA metabolism, and dietary AA undergo 
significant splanchnic first-pass metabolism that is mediated by both the intestinal 
microbiome and the host83. Enterocytes actively regulate AA and di- and tripeptide 
absorption and release139, and AA are cycled between mucosa and lumen140,141. Splanchnic 
retention of dietary AA varies between different AA83,140,142 and systemic availability of a 
quantity fed enterally can be as low as 10% or less for glutamine, glutamate, or aspartate, but 
over 100% - i.e. net synthesis in the splanchnic organs - for alanine, arginine, or tyrosine142. 
4.1.2 Regulation of protein turnover 
Regulatory mechanisms of protein turnover exist on the whole-body, organ/tissue, and 
cellular level and have growth-related, long-term homeostatic, cyclic, and adaptive 
components130. Protein turnover is controlled through synthetic and proteolytic pathways in a 
complex system that is modulated at transcriptional and translational levels130. Proteolysis 
and protein synthesis are intracellular processes that are specifically regulated depending on 
the substrates involved130.  
Global and regional protein metabolism varies cyclically between the fed vs. fasted state. 
Protein utilization and AA metabolism are modulated by substrate availability and hormonal 
response to food intake. Postprandial metabolism is characterized by a net flow of AA from 
the splanchnic organs to skeletal muscle, with plasma insulin and AA concentrations as the 
most important regulators and mTOR-dependent pathways the most important intracellular 
signal transduction systems130,134. In fasting, net AA flow is reversed, with AA – 
predominantly glutamine and alanine – being released from skeletal muscle to provide 
substrates for protein synthesis and hepatic gluconeogenesis. 
4.1.3 Protein balance and metabolic pools 
Protein metabolism, being in a state of constant AA turnover, can be quantified using the 
concept of protein balance. Protein balance is, by definition, the arithmetic difference 
between protein synthesis and breakdown, where a negative value (i.e. breakdown > 
synthesis) represents a catabolic balance and a positive value (synthesis > breakdown) an 
anabolic balance. It can be defined for specific organs and tissues or the whole-body and can 
be measured by nitrogen balance or AA tracer techniques143,144. Calculation of nitrogen 
balance is based on measuring total input of protein/AA and output of AA metabolic products 
over a period of time. While simple in principle, its use in practice is restricted by tedious and 
imprecise procedures of collecting complete or representative samples of excreta, and by the 
slow turnover of WB protein, which makes the method unattractive for the study of rapid 
metabolic changes. Furthermore, nitrogen balance does not allow insights into specific 
processes of AA turnover, such as measures of protein synthesis and proteolysis or organ-
specific metabolism. 
In physiological study, metabolic pools can be defined, which are volumes of distribution that 
may correspond to body compartments, organs, or tissues, but may also be more abstract, 
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operationally defined, entities145. Mass transport of AA is then conceptualized as a system of 
metabolic fluxes, here understood as the rate of AA turnover into, out of, or between pools.  
4.1.4 Isotope labeled amino acid tracers 
Since their development in the early 1930’s, tracers have been an indispensable tool in 
metabolism research146,147. A tracer is a molecular analogue of some target molecule - the 
tracee - that chemically and biologically behaves nearly identically, but can be distinguished 
analytically148. AA tracers are a tool for the study of human protein metabolism in vivo. They 
can be used in several ways, such as by enriching a substrate pool for protein synthesis and 
measuring tracer incorporation in the product, or by using variations of the indicator dilution 
method for measurement of substrate fluxes between AA pools. 
To be usable as a tracer, an AA is labeled, i.e. chemically modified to contain radioactive or 
stable isotopes in specific positions of the molecular structure. In studies of human 
metabolism, stable isotope labels are preferred to minimize radiation exposure. With stable 
isotope labels of e.g. hydrogen, carbon, nitrogen, or oxygen, the molecular mass of the 
labeled compound differs from that of the most common natural form and this difference can 
be measured by mass spectrometry. In the context of AA metabolism, the effects of stable 
isotope labeling on chemical and biological processes149 of interest are mostly negligible, thus 
the tracer’s biological behavior can be assumed to reflect that of the tracee. 
4.1.5 Mass spectrometry 
Mass spectrometry (MS) is used to measure the molecular mass of ions. Its fundamental 
principle is the acceleration of ions in a vacuum chamber, where said ions are separated – e.g. 
through deflection in an electromagnetic field - allowing their sorting by electric charge and 
molecular mass, and subsequently recorded in a detector150. Besides its more common use to 
detect, identify and quantify unique compounds in a sample, MS can be used to separate 
different isotopic species of a compound - or fragments of a compound - by molecular mass, 
and determine their relative abundance. Thus it is possible to analyze the proportion of tracee 
to tracer in a sample, which makes MS the essential analytical tool in stable isotope labeled 
tracer studies151. 
Several isotopic species of a molecule may exist. Within a given molecular structure, the 
position of any atom may be occupied by any isotope of the respective element. This results 
in differences of molecular mass depending on the number and atomic mass of isotopes in the 
individual molecule. The details of the isotopic configuration may be described by the terms 
isotopologue (syn. mass isotopomer), referring to species of a molecule that differ in 
molecular mass, and constitutional isotopomer, referring to species that share a summary 
isotopic composition but differ in the position of specific isotopes within the molecular 
structure.  
A mass spectrum is the output of MS in which the abundance of molecule species 
(technically, abundance of ion species) within a sample is plotted against molecular mass 
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(technically, mass-to-charge ratio, m/z). Terminology of ion masses in MS is somewhat 
complex152. When studying known small metabolites, exact mass measurements are not 
required. Masses may instead be described in rounded, integer values as “M + n”, where M 
represents the mass of the most abundant species of a molecule or fragment ion (“base”), and 
n the additional mass of heavier isotopes in atomic mass units. Ion masses are then denoted as 
M + 0 for the “base”, and M + 1, M + 2, … for subsequent heavier isotopologues.  
4.1.6 Gas chromatography-mass spectrometry for analysis of isotopic 
enrichment in AA tracer studies 
One of many technical implementations of the physical principle of MS, gas chromatography 
– mass spectrometry (GCMS)153 is mostly used for analyzing AA in biological samples. In 
GCMS, a gas chromatograph is linked to a mass spectrometer, enabling isolation of 
compounds of interest from a biological sample before MS analysis. Gas chromatography 
requires analytes that are chemically stable and sufficiently volatile at operating temperatures 
in the region of 250-300 °C, which many metabolites - including AA - are not. Therefore, 
preparation of AA samples may require chemical derivatization by e.g. silylation to enable 
analysis by GCMS151. Samples of derivatized AA are then fed from the gas chromatograph 
into the mass spectrometer, where they are ionized and fragmented in an ion source, 
separated by molecular mass in a radiofrequency quadrupole filter, and recorded in a 
detector151.  
The interpretation of mass spectra from GCMS is not straightforward and requires knowledge 
of possible molecular configurations after sample preparation, derivatization, and 
fragmentation in the ion source. To reconstruct the molecular configurations of the ionized 
fragments of the derivatized forms of tracer and tracee, one must consider the isotopic 
background in the natural, unlabeled biological sample and in the final analytes used for 
GCMS, which may include additional compounds used for derivatization151,154. In 
experimental setups using multiple or highly labeled tracers, there may be significant overlap 
of m/z values between tracers, their metabolic products, and naturally occurring species of the 
tracee, which may require dedicated consideration155. 
The isotopic background arises from the natural abundance of isotopes, i.e. the natural, 
relatively stable and approximately uniform isotopic composition of chemical elements in the 
planetary environment. Natural abundance is largely reflected in the biochemistry of living 
organisms. It is assumed that available isotopes may occupy positions in a biomolecule 
stochastically according to their abundance. However, isotopic background is not exactly 
uniform within the biosphere, both because of physical and chemical effects resulting in local 
isotopic fractionation, and because certain pathways of photosynthetic carbon fixation result 
in preferential enrichment of specific isotopologues in some plants156. These effects 
propagate through the food chain and result in subtle differences of isotopic background in 
biological samples. Furthermore, natural abundance implies that several isotopic species of a 
compound, including such that are used as tracers, may occur naturally in a biological 
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sample. These factors necessitate measurements of the baseline isotopic background in tracer 
studies. 
The most abundant naturally occurring isotopes of hydrogen, carbon, nitrogen, oxygen, and 
several other biochemically relevant elements are also the lightest157. For any organic 
compound, a configuration exists that is entirely composed of the lightest respective isotopes. 
For small molecules, this species typically represents the largest fraction occurring 
biologically, which makes it the reference in measurements of isotopic enrichment, denoted 
M + 0 in mass spectra. For calculation of isotopic excess in a sample, MS is run in selected 
ion monitoring (SIM) mode, i.e. monitoring only the part of the mass spectrum that contains 
the ions of interest, and ratios between M + 0 and subsequent isotopologues are recorded. 
Taking into account the isotopic background in the natural, unlabeled sample, this output can 
then be recalculated to determine the isotopic excess154. 
4.1.7 Isotope dilution method 
One major field of application of AA tracers is the measurement of substrate fluxes between 
AA pools by variations of the indicator dilution method. The principle of indicator dilution is 
that an unknown quantity, such as a volume or flux, can be determined by adding a known 
quantity of an indicator to the compartment of interest. The indicator then undergoes dilution 
by mixing with the compartment’s content, and indicator concentration is measured in a 
sample. The quantity of interest can then be calculated from the dilution of the indicator. (In 
the simplest case, it is assumed that 
𝑆
𝑠
 ≈  
𝑁
𝑛
 
where N is the unknown quantity of interest, n the amount of indicator given, S the size of the 
sample, and s the amount of indicator recovered in the sample. Then, N can be calculated by 
𝑁 ≈  
𝑆 × 𝑛 
𝑠 
  
the so-called Petersen-Lincoln estimator.)  
The applicability of indicator dilution methods relies on a number of assumptions, the most 
fundamental of which is that the indicator behaves similarly to the target entity. Further 
assumptions158 include that: 
- the system is in a steady state; 
- pool size is stable; 
- loss of indicator is zero; 
- mixing is complete; 
- perturbation of the system by the indicator is negligible. 
Variations of indicator dilution methods have been used for a wide variety of purposes, from 
estimation of wildlife populations in the 19th century159, to epidemiology of birth defects in 
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the 20th century160, to measurements of body composition (D2O dilution), regional blood 
volume and flow (dye dilution) and cardiac output (thermodilution, lithium chloride 
dilution)158,161.  
In metabolism research, dilution of an isotope labeled tracer can be used to determine the size 
of a metabolic pool or flux and is then imprecisely termed isotope dilution. In accordance 
with the aforementioned fundamental assumption, the tracer is assumed to undergo the same 
metabolic processes as the target metabolite in the organism. With respect to AA/protein 
metabolism, the concept is applied to dilution of AA tracers in the body’s AA and protein 
pools. Specifically, an AA tracer is injected or infused into a metabolic pool, and samples are 
taken from the same pool, or another pool where the tracee and tracer and/or their metabolic 
products are found. Fluxes may then be calculated from the rate of tracer infusion and isotope 
dilution, as expressed by the ratio of isotopic enrichment in infusate and sample. They can be 
expressed as rate of appearance or disappearance of the AA corresponding to the tracer. Rate 
of appearance (Ra) or rate of disappearance (Rd) is generically defined as the concentration 
change of a compound over time162, but is in this context understood to represent a flux into 
or out of a metabolic pool. 
4.1.8 Steady-state whole-body protein turnover 
Besides nitrogen balance techniques, WB protein turnover may be determined by isotope 
dilution of an AA tracer injected or infused into the blood144. WB protein turnover is then 
quantified using some model, which can generically be defined as “a simplified 
representation of a physiological system which has a structure (compartments) with routes of 
exchange of material between them”163. More specifically, AA turnover is conceptualized as 
a system of fluxes, i.e. mass transports, of AA between a body protein pool and AA pools, 
involving processes of AA conversion/synthesis, oxidation/excretion, and dietary intake. 
Under specific assumptions, measured AA fluxes may then be extrapolated to approximate 
processes of protein metabolism *.  
A generic model of WB metabolism could look like the one shown in Fig. 2144. One 
fundamental property of such WB models is that in the steady state the total turnover of AA 
is assumed to equal the flux of AA into the central pool, Ra (defined as the sum of dietary 
intake and protein breakdown), which in turn is equal to the flux of AA out of the central 
pool, Rd (defined as the sum of protein synthesis and loss to metabolic end products)
133. To 
be experimentally usable, any such model requires modification depending on the choice of 
tracers. For example, the generic model subsumes metabolic processes such as AA 
                                                 
* A technical note. Model pools are an abstraction and do not necessarily correspond to anatomical or 
physiological compartments. For example, parameters for some free AA pool may be calculated from plasma 
samples, suggesting that this pool might correspond to the body’s plasma volume. However, distribution 
volumes for purposes of tracer studies may be incompletely defined, e.g. due to exchange with other 
compartments whose kinetics are unknown. Therefore, absent measurements or explicit assumptions about 
specific compartments, any extrapolations about quantities not included in the model should be made with 
caution, if at all. 
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conversion and synthesis into the central pool, and is as such only usable with tracers for AA 
that take part in these processes133. 
 
 
 
Figure 2 A simple generic model of whole-body protein metabolism, showing two metabolic 
pools and principal pathways of protein turnover 
 
 
 
Figure 3 A highly simplified model of whole-body protein metabolism used for EAA tracer 
studies. De novo synthesis and conversion (other than oxidation) of AA are omitted from the 
model.  
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A direct measurement of protein synthesis is not possible without sampling from the protein 
pool. However, AA oxidation or some other step in the final catabolic pathway can be 
measured132. Dietary intake can be recorded, or measured using a tracer, or in the fasting state 
set as zero. As in the generic model, it is then assumed that in metabolic steady state, total 
flux = Ra = Rd, and Ra is taken to represent (WB protein breakdown + dietary intake), and Rd 
to represent (WB protein synthesis + oxidation). Using the three known quantities - Ra, 
dietary intake, and oxidation - protein synthesis can then be calculated as (Rd – oxidation). 
Using an AA tracer, only pools of the respective AA and its metabolites are labeled, enabling 
measurement of turnover of that AA (Fig. 3). The method of interest here is based upon an 
EAA tracer infused into the blood at a constant rate until isotopic equilibrium is reached, 
followed by plasma sampling and measurement of isotopic enrichment. From the isotopic 
dilution of the AA tracer, Ra of that AA can be calculated. It is then postulated that fluxes of 
the representative AA can be extrapolated to total body protein133,144. 
The utility of such measurements relies on a number of underlying assumptions 132,133,144 
beyond those inherent in all indicator dilution techniques, chiefly that: 
- measurements are made in a metabolic steady state; 
- and the metabolism of the representative AA reflects that of total body protein. 
4.1.9 Phenylalanine as a tracer 
In principle, any EAA can be used as a tracer to determine WB protein turnover, but the 
individual metabolic pathways require specific adaptations of the general method133. In the 
most widely accepted method, 1-13C-leucine infusion is used with sampling of exhaled 13CO2 
and plasma leucine or metabolites132. Alternatively, phenylalanine tracers are usable for 
measurements of both WB and muscle protein turnover164,165. 
The sources of phenylalanine in humans are dietary intake, and release from protein by 
proteolysis (Fig. 4). The chief metabolic fates of phenylalanine are incorporation into protein, 
and hydroxylation to tyrosine. The sources of tyrosine are phenylalanine hydroxylation, 
dietary intake, and release from protein by proteolysis. The chief metabolic fates of tyrosine 
are incorporation into protein, and oxidation to fumaric acid and acetoacetate136,165; its role as 
precursor for bioactive amines such as the catecholamines and the trace amines136,166 is 
quantitatively insignificant.  
The method here described comprises several phenylalanine and tyrosine tracers. The first 
step is to use a phenylalanine tracer (such as L-ring-2H5-phenylalanine) to determine the total 
appearance of phenylalanine into plasma (Fig. 5, shown in blue). 
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Figure 4 A schematic overview of phenylalanine and tyrosine metabolism. Modified from 165 
 
 
Figure 5 A phenylalanine tracer used to determine the appearance of phenylalanine into 
plasma. Modified from 165 
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4.1.10 Phenylalanine hydroxylation 
Hydroxylation to tyrosine is the first, irreversible, and rate-limiting step167 of phenylalanine 
catabolism and is catalyzed by phenylalanine hydroxylase, which is primarily located in the 
liver168. Conversion to other metabolites is negligible, unless there is phenylalanine 
hydroxylase deficiency such as in phenylketonuria. Hydroxylation quantitatively 
approximates oxidation to CO2 under certain experimental conditions
169, but does not in itself 
represent the final metabolic fate of phenylalanine and is therefore not a direct measure of 
oxidation. This must be accounted for when considering WB metabolism in a broader 
context, e.g. in comparison with studies using other AA tracers such as L-1-13C-leucine, 
where AA oxidation can be measured from the end product CO2.  
 
 
Figure 6 A phenylalanine tracer and a tyrosine tracer used to determine the appearance of 
phenylalanine and tyrosine into plasma and phenylalanine hydroxylation. Modified from 165 
 
For purposes of WB turnover, phenylalanine hydroxylation can be quantified by tyrosine 
tracers132,164,169,170. To obtain a complete picture, appearance of tyrosine from phenylalanine 
hydroxylation is quantified separately from total appearance of tyrosine. The appearance of 
tyrosine from phenylalanine hydroxylation (Fig. 6, shown in light green) is found from the 
ratio of fluxes of the corresponding compunds, i.e. L-ring-2H4-tyrosine and its parent 
compound L-ring-2H5-phenylalanine. Another tyrosine tracer (such as L-3,3-
2H2-tyrosine) is 
used to measure the total appearance of tyrosine from all sources (Fig. 6, shown in light + 
dark green).  
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Figure 7 Two phenylalanine tracers and a tyrosine tracer used to determine the appearance 
of phenylalanine into plasma, the enteral contribution to phenylalanine appearance, the 
appearance of tyrosine into plasma, and phenylalanine hydroxylation. Modified from 165 
 
 
Figure 8 A model of whole-body protein metabolism as measured using phenylalanine and 
tyrosine tracers, showing processes explicitly measured, processes derived from 
measurements, and processes included as assumptions. Modified from 165 
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4.1.11 Splanchnic first-pass metabolism and quantifying the dietary 
contribution to amino acid availability 
In the fasting state, the only source of an EAA is from proteolysis. In the fed state however, 
EAA from dietary protein intake must be considered separately when a comprehensive 
description of protein turnover is sought133. For that purpose, it is not sufficient to record the 
amount of dietary intake, because like most AA129,142, phenylalanine undergoes extensive 
first-pass metabolism in the splanchnic circulation171. To quantify first-pass metabolism, a 
second phenylalanine tracer (such as L-1-13C-phenylalanine) is given by the enteral route, 
either as a free AA added to food, or incorporated into dietary protein as so-called 
intrinsically labeled protein172,173. From the appearance of the enteral tracer into plasma, the 
contribution of dietary phenylalanine (Fig. 7, shown in light blue) to the total systemic 
appearance into plasma can be calculated, and conversely the splanchnic extraction fraction 
of dietary phenylalanine133.  
4.1.12 Summary of the phenylalanine-tyrosine whole-body protein turnover 
model 
To summarize, the WB model here outlined (Fig. 8) uses a multitude of phenylalanine and 
tyrosine tracers (Fig. 9) and includes processes that are either explicitly measured (viz., total 
appearance of phenylalanine into plasma, appearance of dietary phenylalanine into plasma, 
total appearance of tyrosine into plasma, and appearance of tyrosine from phenylalanine 
hydroxylation into plasma), included as assumptions (phenylalanine hydroxylation as 
approximation of true oxidation), or calculated from measured values (protein breakdown, 
protein synthesis, splanchnic extraction fraction). 
4.1.13 Muscle and leg amino acid kinetics 
AA kinetics in specific organs or tissues can be determined if the organ of interest is 
accessible for biopsies and/or catheterization of regional vessels. Such regional techniques are 
applied extensively in animal experiments, but their use in humans is limited by ethical 
considerations. In the simplest case, substrate net balance can be calculated from arterio-
venous (A-V) mass balance. This requires only measurement of blood flow and substrate 
concentrations in arterial and regional venous samples, but does not allow determination of 
intraorgan breakdown and synthesis rates132,174.  
For the study of muscle AA metabolism, leg or forearm models using AA tracers are used 
extensively, and their physiological properties are well characterized. Properties of multiple-
pool models, including arterial, venous, interstitial, and muscle tissue compartments, may be 
calculated from A-V mass balances in combination with AA tracers132,174. Such techniques 
usually require biopsies. However, a model is possible in which an approximation of muscle 
protein breakdown and synthesis can be quantified, without muscle biopsies, by intravenous 
phenylalanine tracer infusion164. This model makes use of the fact that phenylalanine is not 
metabolized in muscle, other than in protein breakdown and protein synthesis174. Therefore, 
appearance and disappearance of phenylalanine over the arm or leg can be calculated from 
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arterial and regional venous phenylalanine concentrations and isotopic enrichments, plus 
regional blood flow measurement.  
 
 
 
 
 
Figure 9 A molecule zoo. 
- Upper left, unlabeled L-phenylalanine, C9H11NO2, 165.19 g/mol 
- Upper right, unlabeled L-tyrosine, C9H11NO3, 181.19 g/mol, hydroxylation product of 
phenylalanine 
- Middle left, L-ring-2H5-phenylalanine, 170.22 g/mol  
- Middle right, L-ring-2H4-tyrosine, 185.21 g/mol, hydroxylation product of  L-ring-
2H5-
phenylalanine 
- Lower left, L-3,3-2H2-tyrosine, 183.20 g/mol   
- Lower right, L-1-13C-phenylalanine, 166.18 g/mol   
Molecular masses indicated are those of the natural isotopic mix or of the tracer preparation, 
sources: PubChem Open Chemistry Database 175 and manufacturer’s data. Graphics created 
using ACD/ChemSketch 2018.1.1 
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4.2 DIAGNOSTIC AND ANALYTICAL METHODS 
An overview of diagnostic and analytical methods is shown in Table 3. The details are found 
in the respective papers. 
4.2.1 Isotopic analysis 
GCMS is here applied to measure relative abundances of isotopic species of phenylalanine 
and tyrosine, performed on fragments of the silylized AA from plasma samples. For that 
purpose, mass/charge ratios (m/z) are reported as rounded integer values. Ion m/z values here 
used are 336 for phenylalanine, 337 for 13C-phenylalanine and 15N-phenylalanine, 341 for 
2H5-phenylalanine, 466 for tyrosine, 467 for 
15N-tyrosine, 468 for 2H2-tyrosine, and 470 for 
2H4-tyrosine, in atomic mass units.  
The value required for further calculations is the isotopic enrichment of the tracer in a sample. 
To arrive at that value, a correction for isotopic background is applied. First, abundances of 
tracer and tracee in baseline samples are expressed as tracer/tracee ratio (TTR). Then, in 
subsequent samples from the same subject, abundances are also expressed as TTR and the 
background value is subtracted. From that result, the tracer’s isotopic enrichment is expressed 
as atom percent excess (APE) by the formula154 
𝐴𝑃𝐸 =
𝑇𝑇𝑅
𝑇𝑇𝑅 + 1
 × 100% 
and that value is used for further calculations. 
4.2.2 Calculation of leg protein turnover 
Leg protein turnover is reported in study 1. As noted above, the only pathways of 
phenylalanine metabolism in skeletal muscle are those of protein synthesis and breakdown. 
Thus, measurements of phenylalanine concentrations, tracer isotopic enrichments, and blood 
flow are sufficient to approximate Ra and Rd over the leg without a need for muscle 
biopsies164,174. Blood flow was here determined by dye dilution using indocyanine green176. 
4.2.3 Calculation of whole-body protein turnover 
WB protein turnover is reported in studies 1-3. The principles are described in the physiology 
section above, and calculations are elaborated in study 1177 and in reference164. Specific 
assumptions underlying the model are detailed in164 and are chiefly that: 
- free phenylalanine and tyrosine pools are homogenous and mixed; 
- protein breakdown is the only source of free phenylalanine in the fasting state; 
- hydroxylation to tyrosine and incorporation into protein are the only metabolic fates 
of phenylalanine; 
- implicitly, phenylalanine fluxes are representative of WB protein.  
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Specifically, values calculated are: 
- WB flux for phenylalanine, Qp = RaPhe, representing WB protein breakdown, calculated as 
𝑄𝑃 = 𝑖 × (
𝐸𝑖
𝐸𝑝
− 1) 
where i is the tracer infusion rate, Ei is the isotopic enrichment of the infusate, and Ep is the 
isotopic enrichment in plasma; 
- WB conversion (hydroxylation) of phenylalanine to tyrosine, QPT (without tyrosine tracer, 
as in study 1), calculated as 
𝑄𝑃𝑇 = (0.73 × 𝑄𝑃) ×
𝑄𝑃
(
𝐸𝑃
𝐸𝑇
− 1) × (𝑄𝑃 + 𝑖𝑃)
 
where Ep and ET are isotopic enrichments of phenylalanine and tyrosine in plasma, 
respectively, iP is the phenylalanine tracer infusion rate, and 0.73 is a factor representing the 
molar ratio of fluxes of tyrosine and phenylalanine from protein breakdown164,178; 
- WB conversion (hydroxylation) of phenylalanine to tyrosine, QPT (with tyrosine tracers, as 
in studies 2-3), calculated as  
𝑄𝑃𝑇 = 𝑅𝑎 (𝑖𝑛𝑑𝑒𝑝. 𝑇𝑦𝑟 𝑡𝑟𝑎𝑐𝑒𝑟) ×
𝐸𝑇(ℎ𝑦𝑑𝑟𝑜𝑥. 𝑝𝑟𝑜𝑑. 𝑜𝑓 𝑃ℎ𝑒 𝑡𝑟𝑎𝑐𝑒𝑟)
𝐸𝑃
×
𝑅𝑎𝑃ℎ𝑒
𝑅𝑎𝑃ℎ𝑒 + 𝑖𝑃
 
using values for the hydroxylation product of the phenylalanine tracer (i.e. L-ring-2H4-
tyrosine from hydroxylation of L-ring-2H5-phenylalanine) and the independent tyrosine tracer 
(i.e. L-3,3-2H2-tyrosine), where Ep and ET are isotopic enrichments of phenylalanine and 
tyrosine in plasma, respectively, and iP is the phenylalanine tracer infusion rate; 
- WB incorporation of phenylalanine into protein, RdPhe, representing WB protein synthesis, 
calculated as 
𝑅𝑑 = 𝑄𝑃 − 𝑄𝑃𝑇 
- WB protein net balance, calculated as 
𝑅𝑑𝑃ℎ𝑒 − 𝐸𝑛𝑑𝑜𝑅𝑎𝑃ℎ𝑒 
where EndoRaPhe is the endogenous rate of appearance of phenylalanine; 
- Endogenous rate of appearance of phenylalanine, representing WB protein breakdown, 
assumed – in the fasting state – to equal Qp 
𝐸𝑛𝑑𝑜𝑅𝑎𝑃ℎ𝑒 (𝑓𝑎𝑠𝑡𝑖𝑛𝑔) = 𝑄𝑝 
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and - in the fed state - calculated as 
𝐸𝑛𝑑𝑜𝑅𝑎𝑃ℎ𝑒 (𝑓𝑒𝑑) = 𝑄𝑝 − 𝑑𝑖𝑒𝑡𝑎𝑟𝑦 𝑅𝑎𝑃ℎ𝑒 
4.2.4 Contribution of dietary protein to WB protein turnover 
The contribution of dietary protein or AA to WB metabolism is reported in studies 1-3. As 
noted above in the physiology chapter, a second phenylalanine tracer is added to the enteral 
nutrition formula. Calculations are elaborated in study 1177 and are modified from 
reference171. To arrive at the dietary RaPhe used in the previous formula, splanchnic first-pass 
metabolism is accounted for by the following calculations: 
- the rate of appearance of dietary phenylalanine tracer, calculated as 
𝑅𝑎(𝑑𝑖𝑒𝑡𝑎𝑟𝑦 𝑃ℎ𝑒 𝑡𝑟𝑎𝑐𝑒𝑟) =  
𝑖𝑖𝑣
(
𝐸𝑖𝑣
𝐸𝑑𝑖𝑒𝑡𝑎𝑟𝑦
)
 
where iiv is the infusion rate of the intravenous phenylalanine tracer and Eiv and Edietary are 
isotopic enrichments of the intravenous and dietary tracers in plasma, respectively; 
- which is then used to calculate the rate of appearance of dietary unlabeled phenylalanine by 
𝑑𝑖𝑒𝑡𝑎𝑟𝑦 𝑅𝑎𝑃ℎ𝑒 =
𝑅𝑎(𝑑𝑖𝑒𝑡𝑎𝑟𝑦 𝑃ℎ𝑒 𝑡𝑟𝑎𝑐𝑒𝑟)
𝐸𝑃ℎ𝑒 (𝑛𝑢𝑡𝑟𝑖𝑡𝑖𝑜𝑛)
 
where EPhe(nutrition) is the enrichment of the tracer in nutrition; 
Furthermore, splanchnic uptake, calculated as 
𝑃ℎ𝑒 𝑠𝑝𝑙𝑎𝑛𝑐ℎ𝑛𝑖𝑐 𝑢𝑝𝑡𝑎𝑘𝑒 = 𝑃ℎ𝑒 𝑡𝑜𝑡𝑎𝑙 𝑑𝑖𝑒𝑡𝑎𝑟𝑦 𝑖𝑛𝑡𝑎𝑘𝑒 − 𝑑𝑖𝑒𝑡𝑎𝑟𝑦 𝑅𝑎𝑃ℎ𝑒  
which when expressed as a percentage of intake is termed splanchnic extraction fraction.  
4.2.5 Plasma aminograms 
Plasma amino acids were measured by high-performance liquid chromatography (HPLC), 
which can be considered the standard technique for this purpose179,180. The details of the 
technique employed in studies 2-4 are elaborated in reference181.  
4.2.6 Indirect calorimetry 
Resting energy expenditure was determined by indirect calorimetry, using the Deltatrac II 
instrument182, to determine doses of nutrition in healthy subjects (studies 1-2) and in some, 
but not all, ICU patients (studies 2-3). Measurement of energy expenditure by indirect 
calorimetry is the standard technique to guide nutrition in the ICU183 and is recommended in 
current guidelines2. In particular, measurement by the Deltatrac instrument is considered a 
standard technique the ICU184,185. 
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4.2.7 Insulin sensitivity 
In study 1, insulin sensitivity was assessed by QUICKI (“quantitative insulin sensitivity 
check index”)186. The Quicki index is easily calculated from glucose and insulin values in a 
single blood sample taken in the fasting state. It is extensively validated against direct tests 
such as glucose-insulin clamp studies, and yields a meaningful estimation of insulin 
sensitivity under most circumstances187,188. 
4.3 STATISTICAL METHODS 
An overview of statistical methods is shown in Table 4. All studies in this project comprise 
small numbers of study subjects, necessitated by resource intensive experimental setups and 
laboratory procedures. It is acutely understood that results from such unique, small, 
mechanistic studies are to be interpreted with great caution and in the context of relevant 
physiology. It is furthermore understood that any method of statistical inference may be of 
limited usefulness in such a setting189. That notwithstanding, results are presented using 
conventional, and mostly very conservative, statistics for both descriptive and inferential 
purposes. 
In study 4, a test was sought to define a possible periodicity in the time series for tracer 
enrichments and plasma AA. Simulations demonstrated that the Ljung-Box test190 may be 
useful. The Ljung-Box test tests for serial autocorrelation and was here used on residuals 
from a model that removes linear trends, to highlight possible periodicity. 
 
 
 
 Descriptive statistics Statistical tests Other 
Study 1 Mean, standard deviation  Repeated measures ANOVA with post 
hoc analysis using Bonferroni correction 
Mann-Whitney U test 
t test for independent samples 
 
Study 2 Median, range 
Mean, standard error of the mean 
Wilcoxon matched pairs test  
Study 3  Median, range 
Pearson’s correlation coefficient 
Mann-Whitney U test 
Wilcoxon matched pairs test 
Friedman test 
t test for paired samples 
 
Study 4 Median, range 
Coefficient of variation 
Spearman's rank correlation coefficient Ljung-Box test 
Table 4  
Abbreviations: ANOVA, analysis of variance 
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5 RESULTS 
 
All descriptive statistics are reported as median (range) unless indicated otherwise. 
5.1 STUDY 1 
5.1.1 Method evaluation 
This work was dedicated to both method evaluation and the investigation of the anabolic 
response to protein feeding in a population of viscerally obese, insulin resistant subjects. 
Specifically, muscle protein164 and WB protein turnover was calculated as described above in 
detail. The main finding from the methodological perspective was that the tracer methods 
used were workable in this setting. 
5.1.2 Body composition, insulin resistance and free fatty acid metabolism 
Two cohorts of obese women were studied who differed in body fat distribution. The 
criterion for grouping into upper-body obese (UBO) vs. lower-body obese was a waist-to-hip 
ratio (WHR) of >0.85 vs. <0.80. Although the WHR criterion has its limitations for this 
purpose191, it has been shown to sufficiently discriminate between metabolic phenotypes, 
specifically with respect to deficient insulin-mediated postprandial lipolysis suppression192, 
but also to insulin sensitivity of carbohydrate metabolism191.  
In the cohorts here studied, UBO subjects had a greater amount of visceral fat as measured by 
single-slice computed tomography. Baseline insulin sensitivity was lower, baseline plasma 
free fatty acid (FFA) concentrations were similar and postprandial FFA suppression was less 
pronounced in the UBO group. These findings confirm that the UBO cohort is sufficiently 
representative of the viscerally obese, insulin resistant phenotype of obesity191. 
5.1.3 Protein turnover 
Protein turnover was calculated before and after a mixed meal. The main findings for muscle 
protein turnover were that net protein balance shifted from negative, i.e. catabolic, in the 
fasting state to zero after feeding. There were no differences between groups. The main 
findings for WB protein turnover were that in response to feeding, phenylalanine 
hydroxylation increased somewhat and WB net protein balance switched from negative, i.e. 
catabolic, to positive, i.e. anabolic. Net protein balance after feeding was less positive in the 
UBO group.  
5.2 STUDY 2 
5.2.1 Method evaluation 
Here the experimental protocol previously used in study 1 was modified in two ways. Firstly, 
enteral nutrition contained casein intrinsically labeled with L-1-13C-phenylalanine172 to 
determine the contribution of dietary protein to WB protein turnover. Secondly, tyrosine 
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tracers were used for a more accurate determination of WB phenylalanine hydroxylation. The 
protocol was first investigated in a proof-of-concept experiment in six healthy subjects to 
ensure workability and the attainment of sufficient isotopic enrichment in plasma samples. 
The response of WB protein turnover to feeding was then studied in ten critically ill patients. 
5.2.2 Patients and nutrition 
The cohort studied consisted of ten patients in an early phase of critical illness. They were 
recruited from the ICU at Karolinska University Hospital Huddinge and represent a 
population fairly typical of a mixed adult ICU at a tertiary referral hospital, in that they were 
elderly with an age of 73.5 (65-79) years and were rather ill with APACHE 2 scores of 
25.5 (19-40) and SOFA scores of 7.5 (3-12). Main diagnoses at ICU admission were surgical 
in three and medical in seven. Six patients died within 30 days, one within one year after ICU 
admission, and three were alive after one year. 
Experiments were performed at 55.5 (34-87) hours after ICU admission. Patients were not 
previously enterally fed but received parenteral nutrition. Study nutrition was composed of 
intrinsically labeled casein and maltodextrin at a hypocaloric-hyponitrogenous dose and was 
administered by continuous infusion over 6 hours. The dose of parenteral nutrition was not 
standardized for purposes of the study and patient charts were reviewed in two-hours 
intervals to document the amount of nutrients given parenterally. There was variable nutrient 
supply during the experiment in five patients, with variation exceeding 50% of the maximum 
value in three.  
 
 
 
 
Table 5 Plasma amino acid concentrations in healthy subjects and in critically ill patients 
on parenteral vs. parenteral plus hypocaloric-hyponitrogenous, continuous, enteral protein 
feeding. Data denote median (range). P values for within-group comparison by Wilcoxon 
matched pairs test.Values in µmol/L, averaged from measurements at timepoints 120-150 
min for PN, at 480-510min for PN+EN. Essential AA represent His, Thr, Val, Met, Trp, 
Phe, Ile, Leu, Lys; nonessential AA represent Glu, Asn, Ser, Gln, Gly, Arg, Ala, Tyr. 
Abbreviations used: AA, amino acid(s), PN, parenteral nutrition, EN, enteral nutrition 
 
 Healthy (n=6)  Patients (n=10) 
 PN PN+EN p  PN PN+EN p 
Essential AA  1248 (940-1566) 1382 (1070-1539) 0.116  924 (497-1533) 1009 (571-1730) 0.241 
Nonessential AA 1839 (1478-2072) 1900 (1364-2281) 0.753  1524 (703-2702) 1607 (676-2760) 0.333 
Phenylalanine 96 (83-130) 114 (80-132) 0.116  105 (64-299) 121 (76-309) 0.005 
Leucine 145 (116-190) 154 (126-169) 0.753  105 (73-195) 118 (67-170) 0.646 
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5.2.3 Findings 
Results are reported for both healthy subjects and critically ill patients. However, between-
group comparisons by statistical tests were not done in consideration of the great differences 
in physiology between those groups.  
Plasma AA concentrations, calculated as the sum of essential AA and the sum of nonessential 
AA, showed great variability, particularly in critically ill patients (Table 5). Changes between 
fasting and fed states could not be statistically ascertained. Except for phenylalanine and 
leucine, detailed analyses of individual AA were not performed.  
Uptake of dietary phenylalanine into arterial plasma was documented as the time course of 
plasma 13C-phenylalanine isotopic enrichment in 30 minutes intervals during the experiment. 
The main findings here were that: 
- there is great inter-individual variability 
- uptake is detectable promptly in healthy in healthy subjects but delayed in patients 
(Fig. 10) 
- uptake remains near zero in several patients 
- uptake reaches a tentative steady state after approximately 3 hours in healthy subjects, 
but later in patients (Fig. 11) 
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Figure 10 Isotopic enrichment of L-1-13C-phenylalanine from dietary intrinsically labeled 
casein in arterial plasma of n=6 healthy volunteers (A) and n=10 critically ill patients (B) 
receiving early enteral feeding. Data are shown for individual subjects and medians (dashed 
line). APE, atom percent excess. 
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Figure 11 Mean (±SEM) isotopic enrichment of L-1-13C-phenylalanine from dietary 
intrinsically labeled casein in arterial plasma of healthy volunteers (n=6, shown as circles) 
and critically ill patients (n=10, shown as squares) receiving early enteral feeding. 
Unweighted moving averages were calculated for individual subjects over n=5 consecutive 
measurements. APE, atom percent excess. 
 
The related parameter of splanchnic extraction fraction of dietary phenylalanine was found to 
be high with values of 80 (60-91) % in healthy subjects and 92 (86-99) % in patients. 
Protein turnover was characterized as WB protein breakdown, synthesis, and net balance, as 
well as phenylalanine hydroxylation (here termed Phe conversion). In healthy subjects, no 
changes of these parameters before vs. after feeding were seen (p = 0.173 to 0.917 by 
Wilcoxon’s matched pairs test). In critically ill patients, there was great inter-individual 
variation of all parameters at both timepoints and changes between timepoints were small 
(p = 0.047 to 0.139). 
In three patients, ongoing parenteral nutrition was found to be highly variable over time. 
Results for the remaining seven patients were analyzed separately, the rationale being that 
WB protein turnover is modulated by total AA availability, hence effects of nutritional 
intervention would be difficult to discern when confounded by varying AA supply from 
another source. In these seven patients, changes from fasting to fed states were small on 
average. A small gain in protein net balance was found, with patients becoming less catabolic 
with a net balance of -8.6 (-22.6 to +1.3) µmol phenylalanine x kg-1 x h-1 before feeding vs. -
5.8 (-20.0 to +3.4) µmol phenylalanine x kg-1 x h-1 after feeding (p = 0.018). 
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5.3 STUDY 3 
In study 3, results are reported on: 
- a method evaluation study designed to investigate the equivalence of two 
phenylalanine tracers given enterally, namely the protein-bound  
L-1-13C-phenylalanine used previously in study 2, and L-ring-2H5-phenylalanine 
given as a free AA together with study nutrition  
- an investigation of WB turnover in critically ill patients before vs. after three hours of 
parenteral AA supplementation 
- a repeated investigation of WB turnover, by the same experimental protocol and in 
the same patients, after several days in the ICU.  
5.3.1 Method evaluation study 
Here it was investigated whether the intrinsically labeled casein previously used in study 2 
might be replaced with a free AA tracer. The relevant physiological differences between free 
vs. protein-bound dietary AA are related to digestion and enteral absorption, processes which 
may be affected by critical illness. Therefore, this study was conducted in critically ill 
patients and not in healthy subjects. 
Six patients were recruited from the ICU at Karolinska University Hospital Huddinge. Their 
age was 70 (61-79), SAPS III score was 73 (41-76), SOFA score was 8 (1-12), and main 
diagnoses at ICU admission were surgical in four and medical in two. The study was 
performed on day 4 (3-48) after ICU admission. Enteral feeding was given in a protocol 
similar to that from study 2, combining maltodextrin, casein intrinsically labeled with  
L-1-13C-phenylalanine, and the free L-ring-2H5-phenylalanine tracer. Isotopic enrichments of 
the two tracers were measured in plasma samples over 6 hours and their rates of appearance 
into plasma were calculated, with no correction for splanchnic extraction.  
No uptake into plasma of either tracer was seen in one patient. In the remaining five, Ra of the 
protein-bound tracer was initially higher, but Ra values for both tracers equilibrated after no 
more than three hours of infusion. It was concluded that given sufficient infusion time, the 
phenylalanine tracer administered as a free AA in combination with enteral nutrition is 
suitable to represent phenylalanine from dietary protein in critically ill patients. 
5.3.2 Whole-body protein turnover study 
5.3.2.1 Patients and nutrition 
For the WB turnover study, fourteen patients were initially recruited, but several were lost to 
subsequent experiments because of logistical or medical problems. Thirteen had WB protein 
turnover studied at the first timepoint before and after intervention, ten of these at the second 
timepoint before intervention, and seven of these ten at the second timepoint before and after 
intervention. Patients’ age was 69 (46-77), 71 (46-77) and 71 (46-77), respectively, for the 
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above-named subgroups; SAPS III score was 70 (54-93), 70 (54-93), and 73 (54-93); main 
diagnoses at ICU admission were (surgical/medical) 6/7, 6/4, and 4/3.  
Nutrition schedules were not standardized for purposes of this study.  Total energy and 
protein intake varied between patients and timepoints and were generally in the 
hypocaloric/hyponitrogenous range (Table 6).  
 
 
 
 
Table 6 Total energy and protein intake in ICU patients before/after intravenous amino acid 
supplementation. Q1: change between basal and post-supplementation values. Q2: change 
between first measurement and second measurement several days later. Q3: effect of amino 
acid supplementation maintained at second measurement?  
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Figure 12 Whole-body protein breakdown (A), protein synthesis (B), protein balance (C) and 
phenylalanine oxidation (D) in critically ill patients during baseline and parenteral amino 
acid supplementation (AA) on 2 study days. On the first study day, 13 patients were studied, 
and on the second study day, 7 of these patients were still being treated in the intensive care 
unit and were studied again. The seven patients studied twice are indicated by continuous 
lines, and the other five studied on day 1 only are indicated by dashed lines. Individual values 
are shown, with the median in red.  
 
5.3.2.2 Response to parenteral amino acid supplementation 
In response to parenteral AA supplementation, plasma AA concentrations increased in all 
patients at both timepoints, and plasma urea concentrations remained unchanged. 
All parameters of WB protein turnover showed a wide inter-individual variation at all 
timepoints. When WB protein turnover was first studied on day 7 (2-14) after ICU admission, 
it was found that WB protein breakdown and phenylalanine hydroxylation remained 
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unchanged after parenteral AA supplementation. WB protein synthesis increased from 
58 (34 to 90) to 65 (40 to 87) µmol phenylalanine x kg-1 x h-1, and WB net protein balance 
switched from catabolic at -4 (-21 to +5) to anabolic at +7 (-10 to +14) 
µmol phenylalanine x kg-1 x h-1 (Fig. 12). Splanchnic extraction fraction of dietary 
phenylalanine decreased from 0.4 (0.2 to 0.6) to 0.2 (-0.1 to 0.9).  
Furthermore, parameters of WB protein turnover were studied at a second timepoint two to 
four days later, with an experimental protocol identical to the first experiment. No change 
over time was seen in basal (i.e. before intervention) WB protein breakdown, phenylalanine 
hydroxylation, WB protein synthesis, net balance, or splanchnic extraction.  
Finally, the response to AA supplementation was compared between the first vs. second 
timepoint of intervention. No difference was seen in any parameter of WB protein turnover.  
5.4 STUDY 4 
In study 4, the time course of uptake of phenylalanine from continuous enteral nutrition was 
studied in healthy subjects and critically ill patients. After a run-in time of 12 hours, ongoing 
nutrition was supplemented with a with free L-1-13C-phenylalanine tracer whose uptake into 
arterial blood was then measured over 12 hours. 
5.4.1 Subjects and nutrition 
Seven male and three female healthy subjects of 23 (20-46) years of age were studied. 
Furthermore, ten critically ill patients were recruited from the ICU at Karolinska University 
Hospital Huddinge. Patients’ age was 64 (44-74) years, SAPS III score was 60.5 (57-85), 
SOFA score was 5.5 (1-10), and main diagnoses were surgical in three, medical in four and 
neurological in three. One patient died on day 37 after ICU admission, and nine were alive 90 
days after ICU admission. Experiments were performed on day 20 (5-41) after ICU 
admission. Nutrition was provided by continuous infusion via nasogastric tube or 
jejunostomy, using a complete enteral formula providing 25 kcal/kg per day for healthy 
subjects, or >80% of calculated or measured energy requirements for patients. 
5.4.2 Findings 
Plasma 13C-phenylalanine isotopic enrichments and concentrations of EAA and total AA 
showed large inter-individual variations at all timepoints, in both healthy subjects and 
critically ill patients. A tentative steady state of 13C-phenylalanine isotopic enrichment - here 
defined as a rolling average value that does not change by more than 5% by including 
additional samples - was reached in all individuals after no more than 270 minutes. 
Individual time series were dominated by timepoint-to-timepoint variation. Expressed as 
coefficient of variation for individual time series, variability of plasma 13C-phenylalanine 
isotopic enrichment was 20.9 (12.3-46.3) % in patients and 25.8 (17.5-30.3) % in healthy 
subjects, variability of plasma EAA concentrations was 10.2 (7.8-13.2) % in patients and 
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10.5 (8.5-18.3) % in healthy subjects, and variability of plasma total AA concentrations was 
8.1 (7.3-9.9) % in patients and 8.6 (6.4-13.3) in healthy subjects. 
To mathematically characterize variability over time, individual time series were tested for 
possible intra-individual periodicity. No evidence of periodicity was found, though 
simulations showed that a shorter sampling interval would be required to give the test an 
appropriate sensitivity for the type of data at hand. 
Finally, co-variation between timepoint-to-timepoint changes of 13C-phenylalanine isotopic 
enrichment and plasma EAA concentrations was found to be significant in three of ten 
patients and in nine of ten healthy subjects. 
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6 DISCUSSION 
 
6.1 METHODS 
Tracer studies allow unique insights into metabolic processes but require caution in the 
interpretation of findings. In this section, it is outlined what may and may not be concluded 
from the findings previously described. 
Tracer studies are subject to a trade-off between invasiveness and the information that can be 
gained. In human in vivo experiments, ethical and practical considerations restrict the range 
of anatomical sites accessible for tracer administration and sampling. The techniques 
discussed here require access to: arterial and venous blood, plus possibly enteral infusion for 
WB protein turnover; arterial and femoral venous blood for muscle protein turnover; and 
arterial blood and enteral infusion for enteral AA uptake. These are minimally invasive 
methods and consequently, the information obtainable is restricted to AA turnover in plasma 
and in skeletal muscle, and a limited description of dietary AA uptake into plasma.  
Furthermore, calculations of substrate turnover rest upon assumptions about physiology and 
methodology that are not always explicitly stated but should be understood to appraise 
results. Underlying assumptions for tracer techniques are outlined in the respective sections 
above and are discussed further in the following sections. 
6.1.1 Whole-body protein turnover 
No method of measuring WBPT in human subjects can be regarded as “true” and (…) even if 
we had such a model, we would not be able to determine that it was “correct”. John 
Waterlow163 
A fundamental weakness of steady state “whole-body” protein turnover is that it is poorly 
defined what it measures, both on a technical and a conceptual level133. Furthermore, the 
validity of the concept rests on assumptions that may be difficult to verify163. A few areas of 
uncertainty are outlined below. 
First, by using plasma labeling and sampling, only such processes can be studied whose 
precursors and products are found in plasma. However, protein breakdown and synthesis are 
intracellular processes and all AA turnover is affected by the exchange between the 
intracellular space and other compartments, as well as by intracellular AA cycling. Neither 
process can be quantified by plasma sampling. Therefore, it may remain uncertain to which 
degree true AA turnover is systematically underestimated in a WB model144. 
Second, tracer recycling, i.e. tracer being incorporated into protein and then released by 
proteolysis during the study period, will affect AA turnover calculations144. Recycling is 
probably not significant under many experimental conditions133, but it cannot be quantified 
from plasma samples. 
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Third, the assumption that relevant compartments equilibrate in steady-state conditions may 
or may not hold true for specific experimental conditions. Slowly equilibrating metabolic 
pools may exist, whose metabolism is not quantitatively represented in plasma fluxes133. 
Fourth, positive changes in some organs or tissues may be offset by negative ones elsewhere, 
so that effects of any intervention may remain undetected, or underestimated, by WB 
methods. 
Fifth, a direct measurement of protein synthesis is not possible without access to the target 
protein pool e.g. by biopsy. Therefore, protein synthesis and balance are calculated indirectly 
from values of total AA appearance into plasma, catabolism, and intake. Of these, catabolism 
(“oxidation”) of the target AA can be measured from isotopic enrichment in metabolic end 
products such as CO2 or urea, or approximated from measurement of the product of some 
irreversible step in the catabolic pathway. These measurements require further assumptions 
about kinetic parameters of metabolic pools in the catabolic pathway, introducing additional 
sources of error. 
Sixth, the necessary underlying assumption of steady state conditions is inherently an 
abstraction, and even in a resting subject changes in metabolism may exist that go undetected 
unless specifically looked for. 
These uncertainties do not invalidate the method, but emphasize that its limitations should be 
recognized. The predicament may be resolved by understanding WB protein turnover as an 
operationally defined concept, i.e. accepting WB turnover as whatever is measured by the 
specific tracer and experimental protocol used. Under that premise, WB turnover studies are a 
reasonable choice to investigate the response to disease or intervention, and to compare 
different cohorts of subjects.  
6.1.2 Phenylalanine/tyrosine tracers 
The method here used in studies 1-3 is minimalistic in that only plasma sampling is required. 
Equally minimalistic are the findings, as only plasma substrate fluxes (of total and dietary 
phenylalanine, plus phenylalanine hydroxylation) are directly measured, and AA intake 
recorded, and no compartment modeling takes place. Two peculiarities of the 
phenylalanine/tyrosine method should be considered, that is to say, the representativeness of 
phenylalanine hydroxylation as a measure of catabolism, and the representativeness of 
phenylalanine turnover as a measure of WB protein turnover. 
Phenylalanine catabolism is assumed to be quantitatively represented by hydroxylation, i.e. 
total catabolism is represented by the first irreversible catabolic step. The assumption is valid 
if, firstly, hydroxylation leads to the only relevant catabolic pathway in phenylalanine 
metabolism. This seems to be the case, as of the other possible pathways of phenylalanine 
catabolism, such as transamination to phenylpyruvate167, none are quantitatively relevant in 
healthy adults165. Secondly, the fraction of total tyrosine flux going into protein synthesis vs. 
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catabolism should be quantifiable165. This is done by using a tyrosine tracer as described 
above.  
The representativeness of phenylalanine turnover as a measure of WB protein turnover is an 
inherent assumption of the method. Fundamentally, WB turnover can be measured as 
turnover of any representative EAA. Tracers for different EAA should then give similar 
results for WB turnover when the respective AA content in protein is taken into account. This 
premise is indeed correct for the endogenous Ra of various EAA when normalized to their 
content in muscle protein133,144. Also, when directly compared in fasting healthy subjects, WB 
turnover calculated from infusions of L-ring-2H5-phenylalanine and L-1-
13C-leucine was 
found to be similar164. Here the authors extensively discuss the significance of values derived 
from leucine oxidation to CO2 vs. phenylalanine hydroxylation, suggesting that the different 
catabolic pathways and different tissues involved imply an independent validation of the 
phenylalanine/tyrosine method.  
6.1.3 Phenylalanine/tyrosine tracers in critically ill patients 
The theoretical advantage of the leucine method – direct measurement of AA oxidation from 
the metabolic end product CO2 – makes it less suitable for ICU patients. To standardize 
values calculated from isotopic enrichment in exhaled CO2, the fraction of CO2 recovered 
from the body’s HCO3- pool during the measurement period must be taken into account. 
Given ICU patients’ alterations in body composition and acid-base balance, and possible 
losses through renal replacement therapy, such recovery would have to be measured 
individually by additional tracer studies, adding theoretical uncertainties and logistical 
challenges. In one study from our group31, both leucine and phenylalanine/tyrosine tracers 
were found to be workable, and it was found that healthy subjects increase AA oxidation in 
response to parenteral feeding (Fig. 13), while ICU patients do not. In another study, WB 
turnover was measured to investigate the response to varying doses of parenteral nutrition in 
critically ill patients, using simultaneous infusions of L-ring-2H5-phenylalanine and  
L-1-13C-leucine193. While WB protein balance was similar when calculated from either tracer, 
it was noted that the phenylalanine tracer showed a change in WB protein synthesis while the 
leucine tracer did not. This discrepancy is not readily explained from the experimental data, 
but it was speculated that the two tracers may reflect different weightings of AA metabolism, 
in that leucine may be more representative of skeletal muscle and phenylalanine more 
representative of liver metabolism.  
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Figure 13 Phenylalanine hydroxylation in healthy subjects before and after parenteral 
nutrition corresponding to 20% of daily energy expenditure given over 3 hrs. p = 0.003 by 
paired t test (unpublished data from 31, reproduced by the authors’ permission) 
 
6.1.4 Splanchnic first-pass metabolism of dietary amino acids 
Measuring WB turnover is conceptually simple when AA intake is either zero, i.e. in fasting 
subjects, or easily measured, i.e. during parenteral feeding. However, when there is an 
exogenous source of AA from dietary protein, that contribution must also be quantified133,144. 
This cannot be done from theory, because digestion, absorption, and splanchnic first-pass 
metabolism vary greatly between different AA142, experimental protocols, and subject 
cohorts. Neither is it practical to experimentally quantify all the physiological processes 
affecting an AA from intake to release into hepatic venous blood and further on to sampling 
in arterial blood (Fig. 14). Rather, these processes in their entirety are treated as a black box 
when measuring the Ra of a dietary AA using a tracer in the nutrition.  
The techniques here discussed rely on a tracer that is either incorporated in intact dietary 
protein (calculation of dietary Ra for WB turnover in study 2 and method evaluation in 
study 3) or added to nutrition as free AA (calculation of dietary Ra for WB turnover in 
study 3 and labeled phenylalanine uptake in study 4). As discussed in more detail in study 2, 
values for the splanchnic extraction fraction of phenylalanine have been reported from below 
30 to nearly 60 percent194,195, depending on experimental protocol and choice of tracer. 
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Intrinsically labeled protein is used extensively172,173 to quantify the Ra of AA from dietary 
sources. However, the validity of the technique has been criticized on conceptual grounds, in 
that tracer dilution by unlabeled AA at various stages in the splanchnic organs may not 
properly be accounted for196,197. That controversy cannot be resolved here. Rather, its 
existence is taken to support the view that findings obtained by these techniques should be 
considered in the context of their respective experimental protocols. 
These arguments support the notion that the phenylalanine/tyrosine method is valid within its 
operational definition, and is to some degree also independently corroborated. It may yield 
meaningful results for the global response of protein metabolism to intervention. However, 
findings from such studies will not directly reveal the location or mechanism of effects, and 
should ideally motivate investigations of the anatomical and biochemical details. 
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Figure 14 A simplified schematic of transport and metabolic steps for dietary amino acids 
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6.2 STUDY SUBJECTS AND (LACK OF) BETWEEN-GROUPS COMPARISONS 
Even though many critically ill patients show a degree of similarities in their clinical course, 
populations of critically ill patients are notoriously heterogenous in their demographics, 
comorbidities, diagnoses, physiology, and outcomes198-200. The patient cohorts seen in 
studies 2-4 are fairly representative of an adult mixed ICU in a tertiary center, but are in 
themselves heterogenous, as exemplified by the diversity of diagnoses, severity of illness 
scores, length of stay, and length of survival. Therefore, any generalization of findings should 
be made with caution.  
Extensive physiological differences between healthy subjects and critically ill patients are 
expected, related to both preexisting morbidity and manifestations of critical illness itself. 
Thus, the findings of between-groups differences in protein metabolism in studies 2 and 4 are 
unsurprising. In study 2, between-groups differences in AA concentrations and parameters of 
WB protein turnover were noted but not formally evaluated. In study 4, characterization of 
the physiological differences between healthy subjects and ICU patients was one aim. 
Variability over time of plasma AA concentrations and 13C-phenylalanine enrichment was 
compared between groups and differences could not be statistically ascertained. Given the 
exploratory nature of the study and the insufficient sampling rate, this finding should not be 
considered definitive.  
6.3 PROTEIN TURNOVER 
The main findings in study 1 were that upper-body (viscerally) obese women have a 
diminished sensitivity of postprandial stimulation of WB protein anabolism, and that they are 
insulin resistant as demonstrated by lower Quicki index and lower postprandial lipolysis 
suppression, compared with lower-body-obese women. Visceral obesity is known to be 
associated with postprandial insulin resistance of fatty acid metabolism192, and insulin 
resistance of glucose metabolism. The pathophysiology of insulin resistance in visceral 
obesity is complex and so is the role of FFA191,201. A “protein-sparing” effect of FFA is 
established202,203, and protein metabolism in obesity has been described as characterized by 
anabolic resistance, although some such findings may be explained by experimental 
conditions with unphysiological plasma insulin or AA concentrations204. As discussed in the 
paper, defective insulin-mediated lipolysis suppression with subsequently elevated plasma 
FFA concentrations and an FFA-mediated suppression of protein anabolism might explain 
the finding of lower postprandial protein accretion. An alteration of myocellular or vascular 
insulin action might be an alternative explanation201. The data available do not allow to locate 
the defect, however.  
One central finding in studies 2 and 3 was that in critically ill patients, net protein balance 
typically increases in response to protein/AA feeding, while AA oxidation does not. 
Specifically, the small amount of enterally supplied protein in study 2 yielded small changes 
of protein turnover, but when analyzed in the subgroup with stable parenteral nutrition, a less 
negative net balance was seen. In the WB turnover investigation in study 3, a more 
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substantial amount of AA supplementation given over three hours was on average sufficient 
to shift net protein balance from the catabolic to the anabolic range. This response remained 
stable when the study was repeated at a later timepoint.  
While these findings show that protein/AA supplementation affects protein turnover in 
diverse cohorts of ICU patients, they are strictly only valid for the specific populations and 
nutrition protocols studied. A broader picture emerges in aggregation with results from other 
studies from our group, where the short-term response to feeding was studied using identical, 
or very similar, methods (Fig. 15). These aggregated data represent diverse ICU patient 
populations, as well as diverse treatment and nutrition protocols, and must therefore be 
interpreted with caution. Nonetheless, several trends are apparent: 
- The relationship between supplemental AA/protein dose and WB protein balance 
holds over a wide range of AA doses 
- By linear regression from these values, it appears that a protein/AA dose in the region 
of 1.2 g/kg BW per day is sufficient for a neutral protein balance 
- Lower and upper thresholds may exist, as no measurements show a positive net 
balance with a protein/AA dose below the region of 0.5 g/kg BW, and no 
measurements show a negative net balance with a dose above the region of 
1.8 g/kg BW 
- Phenylalanine hydroxylation (“oxidation”) remains independent of protein/AA dose 
over a wide range of doses 
Integrating these findings, it might be concluded that in short-term studies, protein/AA 
supplementation in critically ill patients appears to improve WB protein balance, in a dose-
dependent manner, largely irrespective of patient specifics, and that increased oxidation of 
supplemental AA is not induced even at higher doses.  
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Figure 15 Whole-body net protein balance and phenylalanine hydroxylation vs. total 
AA/protein intake. Aggregate values from critically ill patients representing diverse ICU 
patient cohorts and nutrition schemes, studied using phenylalanine/tyrosine tracers. Data 
from references  31, 195, 205, 193 and 206. Regression line and R2 values by linear regression.  
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6.4 CONTINUOUS ENTERAL FEEDING 
Since all models are wrong the scientist must be alert to what is importantly wrong. It is 
inappropriate to be concerned about mice when there are tigers abroad. George Box207  
6.4.1 Variability in plasma aminoacidemia 
Few publications were found where nutrient uptake during continuous enteral feeding was 
reported with high resolution on the time axis. In a study of intragastric vs. jejunal continuous 
feeding in healthy subjects208, aminoacidemia was followed through 12 hrs, though with 
infrequent sampling after the first 4 hrs. Inter-individual variability of total AA and EAA was 
apparently small and a steady state appeared to exist. In a study in enterally fed critically ill 
children209, aminoacidemia and plasma enrichments of enterally infused leucine and 
phenylalanine tracers were documented over 24 hrs with a sampling frequency of one sample 
per hour. There was a high intra-individual variability, with a coefficient of variation of 
plasma enrichments over 24 hrs of up to 38 % for leucine and 35 % for phenylalanine, and 
temporal patterns of variation were described as highly individual and non-circadian. Despite 
the differences in study populations, these findings are similar to those in study 4, where 
variation over 12 hrs was in a comparable range, and similar individual patterns of variability 
were seen. These findings suggest that during continuous enteral feeding, a great temporal 
variability of AA uptake into blood is not unusual in either healthy or critically ill subjects. 
The mechanisms underlying temporal variability in AA uptake may lie in any of the stages 
listed in Fig. 14 and cannot be anatomically localized from the available data. However, one 
candidate mechanism is gastric emptying. Gastric emptying is shared among liquid stomach 
contents and could therefore represent a common source of the variability of  
13C-phenylalanine enrichment and plasma concentrations of EAA derived from dietary 
protein. Significant co-variation in changes of 13C-phenylalanine enrichment and plasma 
concentrations of EAA was seen in 9 of 10 healthy subjects in study 4, which appears to 
support a causal role of gastrointestinal transport. EAA from dietary protein share 
gastrointestinal transport mechanisms with free AA, but require digestion before absorption 
can occur, and individual AA differ in molecular transport mechanisms139 and degree of 
splanchnic first-pass metabolism.  
Furthermore, when measurements of gastric volume are not available, the role of gastric 
emptying might indirectly be inferred by comparing study subjects with intragastric vs. 
postpyloric feeding. In the study by de Betue et al.209, the lowest temporal variation of plasma 
enrichments from dietary leucine and phenylalanine tracers was consistently seen in the 5 (of 
n=8) patients with postpyloric feeding; in our data, the temporal variation for plasma  
13C-phenylalanine enrichment of the two patients fed by jejunostomy was the 2nd and 5th 
lowest of n=10 patients and lower than that of all but one healthy subjects. 
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6.4.2 Anabolic stimulation 
Enteral nutrition in the ICU is typically supplied by continuous infusion, under a rationale of 
minimizing complications such as gastric retention and pulmonary aspiration of gastric 
contents. However, continuous feeding is in many respects unphysiological210,211 and its 
effects on metabolism in critical illness are not well characterized212,213. Research comparing 
continuous and intermittent feeding has mostly focused on pulmonary complications, 
gastrointestinal tolerance214-219, nutrient delivery212,215-217, and glycemic control214. 
Continuous feeding may yield suboptimal anabolic stimulation in critical illness, but evidence 
is scarce and is to some degree based on indirect measurements of protein 
metabolism211,220,221. Indirect evidence suggests that intermittent feeding may result in a better 
anabolic response. In healthy humans, muscle protein synthesis reacts to a rapid rise, rather 
than absolute values, of aminoacidemia222. In a neonatal piglet model, muscle protein 
accretion is greater with intermittent than with continuous feeding223,224, which is ascribed to 
a greater effect of AA- and insulin-mediated proanabolic signaling225. However, intermittent 
feeding appears not superior in terms of muscle protein anabolism in healthy adults during 
prolonged bed rest226 or otherwise227, although hospitalized, malnourished, geriatric patients 
gain more muscle mass when dietary protein is fed in pulses rather than evenly distributed 
over the day228. It remains to be tested whether protein turnover in critically ill patients reacts 
to variations of daily nutrient distribution. 
6.5 OUTLOOK 
After decades of clinical and experimental research in nutrition in critical illness, fundamental 
questions remain insufficiently understood. Current areas of uncertainty related to protein/AA 
feeding are the pathomechanisms of harmful effects, optimal mode and timing of feeding, 
monitoring of nutrition, definition of protein requirements, and individualization of 
treatment77,82. For answers to these interrelated questions, experimental and interventional 
trials with clinical endpoints will be needed. The work here presented does not by itself 
address clinical outcomes. However, designing future studies will require better 
understanding of the unique physiological mechanisms of critical illness. By providing 
findings such as the utilization of exogenous protein/AA for improved WB protein balance 
and the lack of their oxidation, the high splanchnic first-pass metabolism of dietary AA, and 
the variability of AA uptake during continuous enteral feeding, this work should contribute to 
such improved understanding.  
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7 CONCLUSION 
 
A popular narrative in support of AA/protein supplementation in critical illness is that:  
- protein loss and muscle wasting are common in critical illness and are associated with 
poor ICU outcomes; 
- greater muscle mass affords better muscle function, therefore muscle wasting should 
be minimized; 
- AA feeding improves protein balance, therefore AA feeding should ameliorate 
muscle wasting, therefore AA feeding should improve ICU outcomes. 
Apart from its first point, this chain of argument - while physiologically plausible - is 
unproven. Fundamental questions remain open, such as how to best define protein 
requirements in critical illness, how to monitor feeding, and how to allow for the 
heterogeneity of ICU patient groups, diagnoses, stages of critical illness, physiological 
measures such as body composition, and specifics of feeding protocols.  
The studies here presented explore the region of the argument that feeding improves protein 
balance. The main findings are that: 
- the phenylalanine/tyrosine method is usable to study the effects of nutrient supply on 
whole-body protein turnover in healthy subjects as well as in critically ill patients;  
- in populations of critically ill adults, enteral and parenteral protein/AA 
supplementation increases whole-body protein balance; 
- in these patients, protein/AA supplementation does not result in increased AA 
oxidation; 
- splanchnic first-pass metabolism of dietary phenylalanine is high, and in critically ill 
patients very high; 
- continuous enteral feeding yields highly variably uptake of dietary phenylalanine into 
blood. 
Any extrapolation of these findings towards possible clinical benefits of specific feeding 
protocols remains speculative, and interventional studies with clinical endpoints will be 
required to address outcomes in ICU patients. Nonetheless, it is concluded that the findings 
support an essential argument in favor of protein/amino acid supplementation as an 
anticatabolic strategy, namely that amino acids from nutritional supplementation are 
utilizable to improve protein balance. 
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10 ERRATA TO PUBLISHED PAPERS 
 
Study 1 
P. 804, in section 3.1, last sentence, 
“The UBO women had […] a higher fraction of body fat …” 
should read: 
 “The UBO women had […] a lower fraction of body fat …” 
P. 804, in section 3.2, third sentence, 
“… Qpt was unchanged, Rd Phe increased …” 
should read: 
“… Qpt and Rd Phe increased …” 
 
Study 2  
P. 552, in section “WB protein kinetics”, 
“… steady state WB Phe kinetics were calculated as described (21, 22) by using the equations 
defined in reference 23.” 
should read: 
“… steady state WB Phe kinetics were calculated as described (21, 22) by using the equations 
defined in reference 23, except WB conversion of Phe to Tyr (Qpt), which was calculated as  
𝑄𝑃𝑇 = 𝑅𝑎 (2
𝑛𝑑𝑇𝑦𝑟 𝑡𝑟𝑎𝑐𝑒𝑟) ×
𝐸𝑇(1
𝑠𝑡𝑇𝑦𝑟 𝑡𝑟𝑎𝑐𝑒𝑟)
𝐸𝑃
×
𝑅𝑎𝑃ℎ𝑒
𝑅𝑎𝑃ℎ𝑒 + 𝑖𝑃
 
where the 1st tyrosine tracer is the one corresponding to the hydroxylation product of the 
phenylalanine tracer (i.e. L-ring-2H4-tyrosine from hydroxylation of L-ring-
2H5-
phenylalanine), the 2nd tyrosine tracer is the independent tyrosine tracer (i.e. L-3,3-2H2-
tyrosine), Ep and ET are isotopic enrichments of phenylalanine and tyrosine in plasma, 
respectively, and iP is the phenylalanine tracer infusion rate.” 
 
Study 3  
P. 4/10, 2nd paragraph, 4th sentence, 
“… at a rate of 0.083 g/kg/hr total amino acids (equivalent to 1 g/kg/day)…” 
should read: 
“… at a rate of 0.042 g/kg/hr total amino acids (equivalent to 1 g/kg/day)…” 
